摘要
视神经脊髓炎(neuromyelitis optica,NMO)是不同于多发性硬化(multiple sclerosis,MS)的一种中枢神经系统特发性炎性疾病。NMO高度特异性的水通道蛋白4(aquaporin-4,AQP4)抗体的发现,加深了人们对NMO的认识,并扩展了NMO谱系疾病(neuromyelitis optica spectrum disorders,NMOSD)的定义。NMO诊断国际专家组(International Panel for NMO Diagnosis,IPND)对NMOSD诊断标准进行了修订,并达成2015年NMOSD诊断标准国际共识。该诊断标准取消了NMO的个别定义,而将NMO归入NMOSD。同时,根据AQP4抗体表达状态,分为AQP4抗体阳性和AQP4抗体阴性NMOSD。AQP4抗体阳性NMOSD的诊断要求具备6项核心症状之一;AQP4抗体阴性或无法进行AQP4抗体检测的NMOSD的诊断,要求则更为严格,必须有特征性的MRI表现。本文即对2015年NMOSD诊断标准国际共识中的要点进行解读和评论。
(CNS) syndrome distinct from multiple sclerosis (MS). The discovery of highly specific ABSTRACTNeuromyelitis optica (NMO) is an idiopathic inflammatory central nervous system antiaquaporin-4 antibody as a diagnostic biomarker for NMO has enabled recognition of NMO and expanded the concept of neuromyelitis optica spectrum disorders (NMOSD). The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria of NMOSD-International Consensus Diagnostic Criteria for NMOSD, 2015. In this new nomenclature, the individual definition of NMO is cancelled and classified into unified term NMOSD, which is stratified further by serologic testing (AQP4-immunoglobulin G-positive or -negative). One of the core clinical characteristics is necessarily required for patients with AQP4-immunoglobulin G-positive NMOSD. More stringent clinical criteria, with additional neuroimaging findings, is required for diagnosis of AQP4-immunoglobulin G-negative NMOSD or when serologic testing is unavailable. This paper presents the highlights of International Consensus Diagnostic Criteria for NMOSD, 2015, and gives some comments.
出处
《神经病学与神经康复学杂志》
2016年第1期12-16,共5页
Journal of Neurology and Neurorehabilitation
基金
国家自然科学基金项目(编号:81230027)~~
关键词
视神经脊髓炎谱系疾病
诊断标准
指南
水通道蛋白4
Neuromyelitis optica spectrum disorders
Diagnostic criteria
Guideline
Aquaporin-4